Submit a Comment

Oncology Market Adoption Trends - Post ASH Quick Poll Results in Multiple Myeloma

As a continuation of the collaboration between OBR and MDoutlook, we will be presenting you with a series of detailed post-ASH and post-SABCS trends research into the immediate clinical impact and integration of research presented at both meetings. The trends research is based on a series of Quick Polls across the MDoutlook platform of 47,000 cancer treaters globally. Feedback was collected within one week of each meeting and from more than 500 cancer treaters (approx 40% of respondents were attendees). No financial incentives were provided to participants.

The second report covers Multiple Myeloma.

ASH 2010 Annual Meeting: Immediate Impact on Current Clinical Practices Multiple Myeloma (MM)

Lenalidomide Maintenance Will be Used in Half of Multiple Myeloma (MM) Patients, Regardless of the Patient’s Age

Key Conclusions

  • Half of patients with MM are expected to receive lenalidomide maintenance therapy in 2011
    • 20%-25% of oncologists expect to be using lenalidomide in all / nearly all MM patients
    • >10% will not be using any
  • Patient age will have minimal effect; an expected slight decrease in use after the age of 75

 Additional Information

  • Respondents selected the percentage of MM patients in each age group that they treat who they expect to use lenalidomide maintenance therapy for in 2011

The Use of Lenalidomide as Maintenance Therapy for Multiple Myeloma (MM) Continues to be Important in Clinical Practice

Key Conclusions

  • 5 out of 6 respondents rated Abstract 37 as having a High or Very High clinical importance
    • Only 2% rated it Low
  • Suggests strong enthusiasm for the use of lenalidomide maintenance therapy for MM

 Abstract Title

  • Abstract 37: “Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104”

Lenalidomide Maintenance Therapy for Multiple Myeloma (MM) is Very Positively Rated by the Oncology Community

Key Conclusions

  • Even with some concerns of secondary malignancies with its use, lenalidomide maintenance therapy for MM is very highly rated by most oncologists
    • Nobody rated lower than 3
  • Average rating = 7.6

*Rating was done on a 10 point scale; 1= lowest to 10 = highest

Abstract Title

  • “Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone In Patients ≥ 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs Fixed-Duration Regimens

Pomalidomide is Expected to Play an Important Role in the Future Management of Multiple Myeloma (MM)

Key Conclusions

  • Most oncologists (~90%) are aware about the development of pomalidomide as a therapeutic for MM
  • It is widely expected that pomalidomide will have a very important clinical impact in those patients for whom it is used
    • Relatively even split between beliefs pomalidomide will be used in a majority or only a specific subset of myeloma patients

Abstract Title

  • Abstract 859: “Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02”

Carfilzomib is Expected to Play an Important Role in the Future Management of Multiple Myeloma (MM)

Key Conclusions

  • Most oncologists (>85%) are aware about the development of carfilzomib as a therapeutic for MM
  • It is widely expected that carfilzomib will have an important clinical role in MM
    • Unsure if carfilzomib will have a large impact on small group of patients or a small impact on large group of patients

Abstract Titles

  • Abstract 985: “Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)”
  • Abstract 3031: “Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)”

Conclusions from the ASH 2010 Quick Poll on Multiple Myeloma (MM)

  • Maintenance therapy with lenalidomide is seen as a highly important advance in the management of MM
  • In 2011, it is expected that half of MM patients will receive lenalidomide maintenance therapy
  • Double the percentage of oncologists who will use it in all / nearly all of their MM patients as compared with those who will use it none of their MM patients
  • Little influence of patient’s age, although slightly less use in those over 75 years of age
  • Two new drugs being developed for MM, the IMiD palmalidomide and the proteasome inhibitor carfilzomib, are both widely expected to have a very positive impact on the clinical landscape

Final Thoughts

Quick polls are a fast way of measuring expected acceptance of clinical data post major medical meetings, and perhaps can be used to make some assumptions about adoption amongst providers. In today’s information hungry environment, the speed at which these polls can be conducted and analyzed can be advantageous for market planning and “pressure testing” acceptance of data amongst key stakeholders.

Submitted by Jan Heybroek, President, The Arcas Group

Email Jan Heybroek

You must be logged in to post a comment